A Phase 4 interventional study of 18-F-Flortaucipir in Alzheimer Disease, sponsored by Mayo Clinic. Recruiting at 2 sites in United States. Open to female participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-24.
Sponsored by Mayo Clinic · Phase 4, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing flortaucipir in Alzheimer Disease — 4 open to participants now, 4 under way, none of them phase 3. flortaucipir · Alzheimer Disease.
Among the 22 studies testing flortaucipir in Alzheimer Disease, this one has the largest planned enrollment, is one of 3 that started in 2019, is the only one in phase 4, and was the 17th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →4 of the 22 studies testing flortaucipir in Alzheimer Disease are open now, in 2 countries. Recruiting first, the newest first:
Eli Radiopharma · Sites in China
Ages 50–85 · Healthy volunteers
University of Alabama at Birmingham · Sites in United States
Ages 50+ · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 21–80
By country, each count listing its studies:
flortaucipir: first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 60 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 7 · Phase 3 4 · Phase 4 1
First in 2013; this study’s year is marked. 3 started in 2019.
This study's planned enrollment of 614 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 70 across the 22 interventional studies. Of the 17 that completed or were terminated, 15 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 22 have an industry lead sponsor. The 6 most frequent:
Mayo Clinic is the lead sponsor of 3,272 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.
21 studies in Alzheimer Disease by Mayo Clinic: 8 open now, 10 under way, none of them phase 3. Of 10 finished, 2 (20%) have results posted.
Among the 21 studies in Alzheimer Disease by Mayo Clinic, this one is the 2nd largest by planned enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2019, is one of 2 in phase 4, and was the 10th registered.
Mayo Clinic’s Alzheimer Disease studies by the year they started, since 2005.
2 of the studies testing flortaucipir in Alzheimer Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07580703Eli RadiopharmaA Phase I Study of [18F]Flortaucipir PET Imaging in Chinese Subjects: Safety, Pharmacokinetics, Biodistribution, Radiation Dosimetry, and Preliminary Diagnostic Efficacy | 2026-12-31 |
| NCT02740634Mayo ClinicMolecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies testing flortaucipir in Alzheimer Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Mayo Clinic’s 21 in Alzheimer Disease:
This tab as a report to print or save as PDF → With an account.
The researchers are trying to determine whether ovarian hormones are associated with aging processes and with the risk of developing Alzheimer's disease in women.
The proposed project will enroll a total of 614 women.
Mayo Clinic Rochester Participants: Each women will have 2-3 clinic visits consisting of cognitive testing, tests of physical function, questionnaires, and a blood draw. All women will also undergo clinical neuroimaging, which includes structural MRI, β-amyloid (Aβ) deposition on PET as a biomarker of Aβ pathology, and tau deposition on PET as a marker of neurofibrillary tangles using AV-1451. All participants will have previously participated and will return by invitation only.
Mayo Clinic Jacksonville Participant: Only African American Women will be enrolled at this site. Each women will have 1-3 clinic visits consisting of physical function testing and neuroimaging, which includes structural MRI, β-amyloid (Aβ) deposition on PET as a biomarker of Aβ pathology, and tau deposition on PET as a marker of neurofibrillary tangles using AV-1451.
Mayo Clinic Rochester-
Inclusion Criteria:
Exclusion Criteria:
Mayo Clinic Jacksonville-
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
18F-Flortaucipir and 11C-Pittsburgh compound-B radioligands will be used for experimental PET imaging of beta-amyloid and neurofibrillary tau pathology
Drug: 18-F-Flortaucipir
Radioligands for PET imaging of beta-amyloid and neurofibrillary tangle tau pathology
Also known as: 11C-Pittsburgh Compound-B
18F-Flortaucipir PET imaging
Cortical 18F-Flortaucipir PET imaging measured once in each participant
Time frame: 1 day
Pittsburgh compound-B PET imaging
Global cortical SUVR measured once in each participant
Time frame: 1 day
Plan to share: No
Started Jun 2019 (actual). Primary completion is estimated for May 2030, 131 months after the start.
Of 42 phase 4 interventional studies under Alzheimer Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 67. This study's planned 131 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Flortaucipir